

2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Samsara BioCapital | March 2017 | $500M | $310M | 57 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Michael Dybbs | Selective | Biotech & pharma, Digital health | 8 | 2 |
| Srinivas Akkaraju | Quiet | Biotech & pharma | 9 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Categories of Samsara Biocapital’s own portfolio companies, based on 15 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Samsara Biocapital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Versant Venture Capital | 2 | Chinook Therapeutics U.S., Tentarix Biotherapeutics |
| Aditum Bio | 1 | vTv Therapeutics |
| Advent Life Sciences | 1 | Versartis |
| Alta Partners | 1 | SUTRO BIOPHARMA |
| ARCH Venture Partners | 1 | Syros Pharmaceuticals |
| Energize Ventures | 1 | Levo Therapeutics |
| Foresite | 1 | ALUMIS |
| Medicxi | 1 | Versartis |
| Novalis Lifesciences Investments | 1 | vTv Therapeutics |
| Polaris Partners | 1 | Syros Pharmaceuticals |
| Rogue | 1 | vTv Therapeutics |
| SR One | 1 | Principia Biopharma |
| SV Life Sciences | 1 | SUTRO BIOPHARMA |
| Venbio Global Strategic | 1 | ALUMIS |
A shared board seat: a company where filings name a Samsara Biocapital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.